Cargando…

A lateral flow immunoassay test performance in SARS-CoV-2 seroprevalence surveys: a validation study among healthcare workers

The objective of this study was to evaluate the validity and reliability of NG-Test® when used as a finger-prick test on healthcare workers and to compare it to the ELISA Wantai Immunoassay. Fifty-one healthcare workers who were RT-PCR SARS-CoV-2 positive and 59 who were RT-PCR SARS-CoV-2 negative a...

Descripción completa

Detalles Bibliográficos
Autores principales: Garlantézec, Ronan, Heslan, Christopher, Tadie, Emilie, Tattevin, Pierre, Thibault, Vincent, Paris, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717860/
https://www.ncbi.nlm.nih.gov/pubmed/33206004
http://dx.doi.org/10.1080/22221751.2020.1852893
_version_ 1783619388421701632
author Garlantézec, Ronan
Heslan, Christopher
Tadie, Emilie
Tattevin, Pierre
Thibault, Vincent
Paris, Christophe
author_facet Garlantézec, Ronan
Heslan, Christopher
Tadie, Emilie
Tattevin, Pierre
Thibault, Vincent
Paris, Christophe
author_sort Garlantézec, Ronan
collection PubMed
description The objective of this study was to evaluate the validity and reliability of NG-Test® when used as a finger-prick test on healthcare workers and to compare it to the ELISA Wantai Immunoassay. Fifty-one healthcare workers who were RT-PCR SARS-CoV-2 positive and 59 who were RT-PCR SARS-CoV-2 negative accepted to participate in this study. They were subjected to an NG-Test® finger-prick test and collection of a blood sample on the same day. A second NG-Test® on another finger was performed for the first 30 cases and controls and read blinded to the first. Sera obtained from blood samples were used to perform the Wantai SARS-CoV-2 ELISA. The interobserver agreement for the NG-Test® test was perfect (kappa coefficient = 100% [98%–100%]). The sensitivity of NG-Test® was estimated to be 85% [71.9%–92.3%] and the specificity 98.3% [95.0%–100.0%]) for both IgG and IgM. The percentage of agreement between the Wantai immunoassay and NG-Test® was 92.73% for IgG (Kappa = 0.85 [0.75–0.95]) and 65.45% (Kappa = 0.42 [0.26–0.58]) for IgM. Our study highlights the need to validate rapid immunoassay tests under real-life conditions. If NG-Test® is used in seroprevalence surveys, we recommend that its diagnostic performance be taken into consideration to obtain a reliable estimation.
format Online
Article
Text
id pubmed-7717860
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-77178602020-12-10 A lateral flow immunoassay test performance in SARS-CoV-2 seroprevalence surveys: a validation study among healthcare workers Garlantézec, Ronan Heslan, Christopher Tadie, Emilie Tattevin, Pierre Thibault, Vincent Paris, Christophe Emerg Microbes Infect Letter The objective of this study was to evaluate the validity and reliability of NG-Test® when used as a finger-prick test on healthcare workers and to compare it to the ELISA Wantai Immunoassay. Fifty-one healthcare workers who were RT-PCR SARS-CoV-2 positive and 59 who were RT-PCR SARS-CoV-2 negative accepted to participate in this study. They were subjected to an NG-Test® finger-prick test and collection of a blood sample on the same day. A second NG-Test® on another finger was performed for the first 30 cases and controls and read blinded to the first. Sera obtained from blood samples were used to perform the Wantai SARS-CoV-2 ELISA. The interobserver agreement for the NG-Test® test was perfect (kappa coefficient = 100% [98%–100%]). The sensitivity of NG-Test® was estimated to be 85% [71.9%–92.3%] and the specificity 98.3% [95.0%–100.0%]) for both IgG and IgM. The percentage of agreement between the Wantai immunoassay and NG-Test® was 92.73% for IgG (Kappa = 0.85 [0.75–0.95]) and 65.45% (Kappa = 0.42 [0.26–0.58]) for IgM. Our study highlights the need to validate rapid immunoassay tests under real-life conditions. If NG-Test® is used in seroprevalence surveys, we recommend that its diagnostic performance be taken into consideration to obtain a reliable estimation. Taylor & Francis 2020-12-01 /pmc/articles/PMC7717860/ /pubmed/33206004 http://dx.doi.org/10.1080/22221751.2020.1852893 Text en © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group, on behalf of Shanghai Shangyixun Cultural Communication Co., Ltd https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Letter
Garlantézec, Ronan
Heslan, Christopher
Tadie, Emilie
Tattevin, Pierre
Thibault, Vincent
Paris, Christophe
A lateral flow immunoassay test performance in SARS-CoV-2 seroprevalence surveys: a validation study among healthcare workers
title A lateral flow immunoassay test performance in SARS-CoV-2 seroprevalence surveys: a validation study among healthcare workers
title_full A lateral flow immunoassay test performance in SARS-CoV-2 seroprevalence surveys: a validation study among healthcare workers
title_fullStr A lateral flow immunoassay test performance in SARS-CoV-2 seroprevalence surveys: a validation study among healthcare workers
title_full_unstemmed A lateral flow immunoassay test performance in SARS-CoV-2 seroprevalence surveys: a validation study among healthcare workers
title_short A lateral flow immunoassay test performance in SARS-CoV-2 seroprevalence surveys: a validation study among healthcare workers
title_sort lateral flow immunoassay test performance in sars-cov-2 seroprevalence surveys: a validation study among healthcare workers
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717860/
https://www.ncbi.nlm.nih.gov/pubmed/33206004
http://dx.doi.org/10.1080/22221751.2020.1852893
work_keys_str_mv AT garlantezecronan alateralflowimmunoassaytestperformanceinsarscov2seroprevalencesurveysavalidationstudyamonghealthcareworkers
AT heslanchristopher alateralflowimmunoassaytestperformanceinsarscov2seroprevalencesurveysavalidationstudyamonghealthcareworkers
AT tadieemilie alateralflowimmunoassaytestperformanceinsarscov2seroprevalencesurveysavalidationstudyamonghealthcareworkers
AT tattevinpierre alateralflowimmunoassaytestperformanceinsarscov2seroprevalencesurveysavalidationstudyamonghealthcareworkers
AT thibaultvincent alateralflowimmunoassaytestperformanceinsarscov2seroprevalencesurveysavalidationstudyamonghealthcareworkers
AT parischristophe alateralflowimmunoassaytestperformanceinsarscov2seroprevalencesurveysavalidationstudyamonghealthcareworkers
AT garlantezecronan lateralflowimmunoassaytestperformanceinsarscov2seroprevalencesurveysavalidationstudyamonghealthcareworkers
AT heslanchristopher lateralflowimmunoassaytestperformanceinsarscov2seroprevalencesurveysavalidationstudyamonghealthcareworkers
AT tadieemilie lateralflowimmunoassaytestperformanceinsarscov2seroprevalencesurveysavalidationstudyamonghealthcareworkers
AT tattevinpierre lateralflowimmunoassaytestperformanceinsarscov2seroprevalencesurveysavalidationstudyamonghealthcareworkers
AT thibaultvincent lateralflowimmunoassaytestperformanceinsarscov2seroprevalencesurveysavalidationstudyamonghealthcareworkers
AT parischristophe lateralflowimmunoassaytestperformanceinsarscov2seroprevalencesurveysavalidationstudyamonghealthcareworkers